Patients with early-stage recurrent hepatocellular carcinoma and sarcopenia face significantly lower overall and recurrence-free survival rates, regardless of treatment type. Sarcopenia emerges as an independent prognostic factor, suggesting a crucial role in long-term outcomes. Notably, impaired host immunity, evidenced by low levels of tumor-infiltrating lymphocytes, may contribute to the unfavorable prognosis. This study underscores the clinical impact of sarcopenia and its association with immune function in recurrent hepatocellular carcinoma patients.
Journal Article by Doi S, Yasuda S (…) Sho M et 7 al. in Langenbecks Arch Surg
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.